ZEISS PALM MicroBeam IV module Rel 4.2

描述（由申请人提供）：本提案要求NCRR支持从Zeiss（P.A.L.M.）采购最先进的PALM MicroBEAM IV激光捕获显微切割仪器（PALM MicroBeam）。Microlaser Technologies，Carl Zeiss Group，Bernried，德国）。该设备将是俄亥俄州州立大学（OSU）共享使用的第一台激光捕获设备。整个俄勒冈州立大学或附近的全国儿童没有激光捕获显微切割（LCM）核心设施。所要求的仪器将存放在俄亥俄州州立大学医学中心（OSUMC）的激光捕获分子核心设施（https：//lcm.osu.edu/index.cfm）中。).空间和相关资源已承诺为拟议的核心，以回应教师的要求。2008年5月，俄勒冈州立大学被授予著名的NIH临床和转化科学奖（CTSA）。LCM新方法开发是该奖项的优先领域。PI与其他两名研究人员一起获得了研究资助，以开发LCM样品的蛋白质组学和miR分析方法。这些方法现在已经准备好传播; OSU CTSA已经宣布为通过激光捕获分子核心向OSU调查人员传播开发的方法提供匹配资金。申请的PALM MicroBeam具有专利的激光显微切割和压力切割（LMPC）技术。在DNA、RNA和蛋白质水平上对病理改变的细胞和组织进行分子检测，彻底改变了病理学的研究和诊断。然而，原发组织的固有异质性与各种反应性细胞群的混合物可能会影响分子研究的结果和解释。LMPC特别适合于研究空间分辨生物学，使研究人员能够分离小至单细胞甚至亚细胞片段的纯细胞群样品，用于进一步的分子分析（基因表达，蛋白质组学）。预计该设备将直接提高至少14个（8个主要用户和6个次要用户）目前资助的联邦研究赠款的生产力，年度直接费用总额超过250万美元。核心设施的长期目标是为OSUMC及其附属研究机构的多元化研究社区提供最新的LCM技术和应用。该仪器拨款申请LCM的资金将改变联邦资助的研究项目在俄勒冈州立大学的能力，提高他们的生产力和竞争力，为未来的校外资助，可以影响NIH和/或其他校外资助的研究在俄勒冈州立大学。 公共卫生相关性：PALM MicroBeam IV是高通量激光显微切割（LCM）设备。使用该技术，可以从临床相关的小组织切片中捕获单个细胞和特定区域，用于基因组和蛋白质组学分析。该技术最适合人类健康相关的转化研究，也是必不可少的。

DESCRIPTION (provided by applicant): This proposal requests NCRR support for the acquisition of state-of-the-art PALM MicroBEAM IV laser capture micro-dissection instrument (PALM MicroBeam) from Zeiss (P.A.L.M. Microlaser Technologies, Carl Zeiss Group, Bernried, Germany). This equipment would be the first laser capture equipment for shared use in the Ohio State University (OSU). The entire OSU or nearby Nationwide Children's do not have a Laser Capture Micro-dissection (LCM) core facility. The requested instrument will be housed in Laser Capture Molecular Core facilities (https://lcm.osu.edu/index.cfm) in the Ohio State University Medical Center (OSUMC). ). Space and relevant resources have been committed for the proposed core in response to faculty requests. In May, 2008 OSU was awarded the prestigious NIH Clinical and Translational Science Award (CTSA). LCM novel methodology development was a priority area in this award. The PI together with two other investigators was awarded research grant to develop proteomics and miR profiling methods from LCM samples. These methods are now ready for dissemination; OSU CTSA has announced matching funds for dissemination of methodology developed via Laser Capture Molecular Core to OSU investigators. The requested PALM MicroBeam has the patented laser microdissection and pressure catapulting (LMPC) technology. The molecular examination of pathologically altered cells and tissues at the DNA, RNA, and protein level has revolutionized research and diagnostics in pathology. However, the inherent heterogeneity of primary tissues with an admixture of various reactive cell populations can affect the outcome and interpretation of molecular studies. Particularly suited to study spatially resolved biology, LMPC enables the investigator to isolate samples of pure cell populations as small as single cells or even sub cellular fragments for further molecular profiling (gene expression, proteomics). The equipment is expected to directly enhance the productivity of a minimum of 14 (8 major users and 6 minor users) currently funded federal research grants totaling > $ 2.5 million in annual direct costs. The long term goals of the core facility are to provide diverse research community of OSUMC and affiliated research institutions with the latest LCM technology and applications. The funding of this instrumentation grant application for LCM will transform the capability of the federally funded research programs at the OSU, increasing their productivity and competitiveness for future extramural funding that can impact NIH and/or other extra mural funded research at OSU. PUBLIC HEALTH RELEVANCE: PALM MicroBeam IV is high-throughput laser microdissection (LCM) equipment. Using this technology, individual cells and specific regions can be captured from clinically relevant small tissue section for genomic and proteomic analyses. The technology is best suited and is essential for human health relevant translational research.